Abbott India Limited (NSE:ABBOTINDIA)

Market Cap	595.17B -14.7%
Revenue (ttm)	69.29B +8.1%
Net Income	15.52B +9.7%
EPS	730.39 +9.7%
Shares Out	n/a
PE Ratio	38.35
Forward PE	34.90
Dividend	656.00 (2.36%)
Ex-Dividend Date	Jul 24, 2026

Volume	8,475
Open	27,535
Previous Close	27,535
Day's Range	27,330 - 28,135
52-Week Range	25,150 - 34,060
Beta	0.06
Analysts	Buy
Price Target	32,652.38 (+16.41%)
Earnings Date	Aug 12, 2026

About Abbott India

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women’s health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1910
• Employees: 3,679
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ABBOTINDIA

Financial Performance

In fiscal year 2026, Abbott India's revenue was 69.29 billion, an increase of 8.11% compared to the previous year's 64.09 billion. Earnings were 15.52 billion, an increase of 9.73%.

Analyst Summary

According to 8 analysts, the average rating for ABBOTINDIA stock is "Buy." The 12-month stock price target is ₹32,652, which is an increase of 16.41% from the latest price.

Price Target

₹32,652

(16.41% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 11, 2026

Data Sources Report a data error